In a Source Weekly (Bend) article about the Community Belonging Measurement Project, a collaboration among OHSU, OSU-Cascades and the Central Oregon Health Councils to address an area of need identified in their regional health plan in 2020 to 2024, Camilla Dohlman discusses her role and says, "One thing that came through really clearly in the data is that belonging is really a driver of health.”

Medscape publishes a brief about an OHSU patient who is the world's first reported case of brain disease from fentanyl inhalation.

An OHSU study finds that when both cannabis and nicotine are used during pregnancy, the rate of infant death increases fourfold. “With the growing legalization of cannabis around the country, there is often a perception that cannabis is safe in pregnancy,” says Jamie Lo, M.D. "Our hope is that this research supports more open and productive conversations that ultimately result in a healthier pregnancy.”

An OHSU study finds that when both cannabis and nicotine are used during pregnancy, the rate of infant death increases fourfold. “With the growing legalization of cannabis around the country, there is often a perception that cannabis is safe in pregnancy,” says Jamie Lo, M.D. "Our hope is that this research supports more open and productive conversations that ultimately result in a healthier pregnancy.”

A Phase I/II clinical trial finds that a CRISPR-based gene editing technology improved vision in 11 of 14 participants who were born with a blindness-causing gene mutation. Mark Pennesi, M.D., Ph.D., says, “As ophthalmologists, we were often taught that there aren't really treatments for these rare genetic diseases. That is changing."

Mitchell Hayes, M.D., gives a presentation at the American Urological Association meeting on his team’s work using advanced techniques to study tumor samples from patients with localized renal cell carcinoma.

A Phase I/II clinical trial finds that a CRISPR-based gene editing technology improved vision in 11 of 14 participants who were born with a blindness-causing gene mutation. Mark Pennesi, M.D., Ph.D., says, “As ophthalmologists, we were often taught that there aren't really treatments for these rare genetic diseases. That is changing."

A Phase I/II clinical trial finds that a CRISPR-based gene editing technology improved vision in 11 of 14 participants who were born with a blindness-causing gene mutation. Mark Pennesi, M.D., Ph.D., says, “As ophthalmologists, we were often taught that there aren't really treatments for these rare genetic diseases. That is changing."

A Phase I/II clinical trial finds that a CRISPR-based gene editing technology improved vision in 11 of 14 participants who were born with a blindness-causing gene mutation. Mark Pennesi, M.D., Ph.D., says, “As ophthalmologists, we were often taught that there aren't really treatments for these rare genetic diseases. That is changing."

A Phase I/II clinical trial finds that a CRISPR-based gene editing technology improved vision in 11 of 14 participants who were born with a blindness-causing gene mutation. Mark Pennesi, M.D., Ph.D., says, “As ophthalmologists, we were often taught that there aren't really treatments for these rare genetic diseases. That is changing."